Markets
Investec initiates buy on Motilal Oswal, sees 25% upside with Rs 1,200 target
Investec has initiated a ‘Buy’ rating on Motilal Oswal Financial Services, setting a target price of ₹1,200, implying a 25%…
Markets
Markets
JPMorgan initiates overweight on Swiggy, sees 27% upside with Rs 730 target
JPMorgan has initiated an ‘Overweight’ rating on Swiggy, setting a target price of ₹730, implying a 27% upside from the…
Markets
Jefferies bullish on midcaps: Recommends Amber, Nykaa, Coforge, and Sunteck for strong EPS growth
Jefferies highlighted the continued outperformance of small and midcap stocks over large caps in 2024, building on their sharp rally…
Markets
UBS on auto sector: December retail trends show decline for Hero and Bajaj, growth for TVS and Eicher
UBS has analyzed the December retail trends for the auto sector, projecting a 7-9% year-on-year decline in overall industry retails…
Markets
Citi on Axis Bank: Focus on delinquencies, deposit growth, and loan mix stabilization
Citi has analyzed the operational performance of Axis Bank, highlighting key aspects that could impact its near-term and long-term growth.…
Markets
Understanding IPO Risks: Essential Information for Investors
Investing in an IPO can be an exciting experience. Popular companies launch their IPOs, often becoming oversubscribed in hours. The…
Markets
Investec initiates buy on Afcons, sees 17% upside with ₹630 target
Investec has initiated a ‘Buy’ rating on Afcons, setting a target price of ₹630, implying a 17% upside from the…
Markets
HDFC Securities sees 23% upside in Mastek, maintains ‘Add’ rating with ₹4,000 target
HDFC Securities has maintained its ‘Add’ rating on Mastek, with a target price of ₹4,000, indicating a notable upside from…
Markets
Kotak on Escorts Kubota: Focus on domestic growth and margin improvement
Kotak has shared key takeaways from the management meet of Escorts Kubota, highlighting the company’s focus on domestic growth while…
Markets
JM Financial initiates buy on Piramal Pharma, sees 35% upside with Rs 340 target
JM Financial has initiated a ‘Buy’ rating on Piramal Pharma, setting a target price of ₹340 per share, implying a…
Markets
Equirus brokerage sees 17% upside in Delhivery, initiates long call with Rs 459 target
Equirus has initiated a ‘Long Call’ on Delhivery, setting a target price of ₹459 per share, implying a 17% upside…
Markets
Morgan Stanley sees 19% downside in Wipro, maintains ‘Underweight’ rating with Rs 250 target
Morgan Stanley has maintained its ‘Underweight’ rating on Wipro, setting a target price of ₹250 per share. The brokerage noted…